People with post-traumatic stress disorder (PTSD) may soon have a new treatment option: MDMA, the chemical found in ecstasy. In August, the Food and Drug Administration plans to decide whether MDMA-assisted therapy for PTSD will be approved for market based on years of research. But serious allegations of research misconduct may derail the approval timeline. NPR science reporter Will Stone talks to host Emily Kwong about the clinical trials on MDMA-assisted therapy research and a recent report questioning the validity of the results. Read Will's full story here. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Short Wave
Transcribed and ready to explore now
Parasites Have Haunted Us For Millions Of Years
24 Oct 2025
Short Wave
Migrating Birds Have a Big, Clear Problem
22 Oct 2025
Short Wave
We Have the Cure. Why is Tuberculosis Still Around?
21 Oct 2025
Short Wave
Should Scientists Genetically Engineer Wild Species?
20 Oct 2025
Short Wave
Science Says Quitting Smoking At Any Age Is Good For The Brain
17 Oct 2025
Short Wave
What Happens When You're Under Anesthesia?
15 Oct 2025
Short Wave